 "Aarti Drugs dips on FDA import alert; trades ex-bonus")
Shares of Aarti Drugs has dipped 14% at Rs 575 on the National Stock Exchange (NSE) in early morning today after the pharmaceutical company gets US FDA (Food and Drug Administration) import alert on its manufacturing plant in Tarapur, Maharashtra.
Meanwhile, the stock turned ex-bonus in the ratio of 1:1 i.e. 1 (one) bonus equity share of Rs 10 each fully paid up for every 1 (one) existing equity share of Rs 10 each fully paid up held in the company.
In past two months, the stock had rallied 24% compared with 3.7% fall in the CNX Nifty after the company announced bonus issue.
The stock opened at Rs 624 and touched a low of Rs 559 on the NSE. A combined 241,130 shares changed hands on the counter on the NSE and BSE so far.
At 0948 hours, the stock was down 12% at Rs 593 on the NSE.
Meanwhile, the stock turned ex-bonus in the ratio of 1:1 i.e. 1 (one) bonus equity share of Rs 10 each fully paid up for every 1 (one) existing equity share of Rs 10 each fully paid up held in the company.
In past two months, the stock had rallied 24% compared with 3.7% fall in the CNX Nifty after the company announced bonus issue.
The stock opened at Rs 624 and touched a low of Rs 559 on the NSE. A combined 241,130 shares changed hands on the counter on the NSE and BSE so far.
At 0948 hours, the stock was down 12% at Rs 593 on the NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%